# Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia

Study · id `cardio:ct-nct07684469` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07684469](<https://clinicaltrials.gov/study/NCT07684469>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07684469

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07684469. Randomized; no masking; primary purpose treatment. Start 2026-10-31 (anticipated); primary completion 2028-02-29 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07684469, source copy `cardio:ctgov-nct07684469-2026-10-30`, retrieved 2026-10-31)
- Planned start: 2026-10-31 (anticipated) (ClinicalTrials.gov record NCT07684469, source copy `cardio:ctgov-nct07684469-2026-10-30`, retrieved 2026-10-31)
- Primary completion: 2028-02-29 (anticipated) (ClinicalTrials.gov record NCT07684469, source copy `cardio:ctgov-nct07684469-2026-10-30`, retrieved 2026-10-31)
- Completion: 2029-02-28 (anticipated) (ClinicalTrials.gov record NCT07684469, source copy `cardio:ctgov-nct07684469-2026-10-30`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07684469-2026-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
- Condition: Acute Coronary Syndrome
- Intervention (Drug): inclisiran
- Intervention (Drug): SOC
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 8d4436591336ea0dea2d0d376035455823bae47ce6ff2dcf02b88843a44dfc88
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
